BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17222197)

  • 1. 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis.
    Ocio EM; Schop RF; Gonzalez B; Van Wier SA; Hernandez-Rivas JM; Gutierrez NC; Garcia-Sanz R; Moro MJ; Aguilera C; Hernandez J; Xu R; Greipp PR; Dispenzieri A; Jalal SM; Lacy MQ; Gonzalez-Paz N; Gertz MA; San Miguel JF; Fonseca R
    Br J Haematol; 2007 Jan; 136(1):80-6. PubMed ID: 17222197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of 6q deletion in Waldenstrom macroglobulinemia.
    Chang H; Qi X; Xu W; Reader JC; Ning Y
    Eur J Haematol; 2007 Sep; 79(3):244-7. PubMed ID: 17655703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance.
    Schop RF; Van Wier SA; Xu R; Ghobrial I; Ahmann GJ; Greipp PR; Kyle RA; Dispenzieri A; Lacy MQ; Rajkumar SV; Gertz MA; Fonseca R
    Cancer Genet Cytogenet; 2006 Sep; 169(2):150-3. PubMed ID: 16938573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study.
    Chang H; Qi C; Trieu Y; Jiang A; Young KH; Chesney A; Jani P; Wang C; Reece D; Chen C
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):36-8. PubMed ID: 19362968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia.
    Bang SM; Seo JW; Park KU; Kim SJ; Kim K; Kim SH; Cho SR; Kim HC; Song J; Kim JS; Kim KH; Lee JH; Lee JJ; Shin MG; Suh C; Chi HS; Oh DY; Won JH; Kim HJ; Yoon SS; Lee DS;
    Cancer Genet Cytogenet; 2010 Mar; 197(2):117-21. PubMed ID: 20193844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival.
    García-Sanz R; Dogliotti I; Zaccaria GM; Ocio EM; Rubio A; Murillo I; Escalante F; Aguilera C; García-Mateo A; García de Coca A; Hernández R; Dávila J; Puig N; García-Álvarez M; Chillón MDC; Alcoceba M; Medina A; González de la Calle V; Sarasquete ME; González M; Gutiérrez NC; Jiménez C
    Br J Haematol; 2021 Mar; 192(5):843-852. PubMed ID: 32780894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asymptomatic Waldenstrom's macroglobulinemia.
    Alexanian R; Weber D; Delasalle K; Cabanillas F; Dimopoulos M
    Semin Oncol; 2003 Apr; 30(2):206-10. PubMed ID: 12720137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
    Vitolo U; Ferreri AJ; Montoto S
    Crit Rev Oncol Hematol; 2008 Aug; 67(2):172-85. PubMed ID: 18499469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smouldering Waldenstrom's macroglobulinemia: factors predicting evolution to symptomatic disease.
    Cesana C; Miqueleiz S; Bernuzzi P; Tresoldi E; Rossi V; D'avanzo G; Filippini D; Morra E
    Semin Oncol; 2003 Apr; 30(2):231-5. PubMed ID: 12720142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit.
    Kyrtsonis MC; Vassilakopoulos TP; Angelopoulou MK; Siakantaris P; Kontopidou FN; Dimopoulou MN; Boussiotis V; Gribabis A; Konstantopoulos K; Vaiopoulos GA; Fessas P; Kittas C; Pangalis GA
    Ann Hematol; 2001 Dec; 80(12):722-7. PubMed ID: 11797112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetics and cytogenetics of Waldenstrom's macroglobulinemia.
    Schop RF; Fonseca R
    Semin Oncol; 2003 Apr; 30(2):142-5. PubMed ID: 12720124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course.
    Mansoor A; Medeiros LJ; Weber DM; Alexanian R; Hayes K; Jones D; Lai R; Glassman A; Bueso-Ramos CE
    Am J Clin Pathol; 2001 Oct; 116(4):543-9. PubMed ID: 11601139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.
    Ghobrial IM; Fonseca R; Gertz MA; Plevak MF; Larson DR; Therneau TM; Wolf RC; Hoffmann RJ; Lust JA; Witzig TE; Lacy MQ; Dispenzieri A; Vincent Rajkumar S; Zeldenrust SR; Greipp PR; Kyle RA
    Br J Haematol; 2006 Apr; 133(2):158-64. PubMed ID: 16611306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH.
    Parry-Jones N; Matutes E; Morilla R; Brito-Babapulle V; Wotherspoon A; Swansbury GJ; Catovsky D
    Br J Haematol; 2007 Apr; 137(2):117-24. PubMed ID: 17391491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion 6q is not a characteristic marker of nodal lymphoplasmacytic lymphoma.
    Cook JR; Aguilera NI; Reshmi S; Huang X; Yu Z; Gollin SM; Abbondanzo SL; Swerdlow SH
    Cancer Genet Cytogenet; 2005 Oct; 162(1):85-8. PubMed ID: 16157207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study.
    Ghobrial IM; Fonseca R; Greipp PR; Blood E; Rue M; Vesole DH; Gertz MA;
    Cancer; 2004 Dec; 101(11):2593-8. PubMed ID: 15493038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemia.
    Kim JA; Im K; Park SN; Kwon J; Choi Q; Hwang SM; Sekiguchi N; Yoon SS; Lee DS; Kim SY
    Biomed Res Int; 2014; 2014():363540. PubMed ID: 24895570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chromosomal abnormalities and Waldenström macroglobulinemia].
    Berger R; Nguyen-Khac F
    Pathol Biol (Paris); 2008 Sep; 56(6):400-6. PubMed ID: 18456427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
    Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromosome band 6q deletion pattern in malignant lymphomas.
    Taborelli M; Tibiletti MG; Martin V; Pozzi B; Bertoni F; Capella C
    Cancer Genet Cytogenet; 2006 Mar; 165(2):106-13. PubMed ID: 16527604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.